NO930199L - Oligonukleotidanaloger, deres fremstilling og anvendelse - Google Patents

Oligonukleotidanaloger, deres fremstilling og anvendelse

Info

Publication number: NO930199L
Authority: NO; Norway
Prior art keywords: aryl; alkyl; preparation; seh; alkoxy
Prior art date: 1992-01-22

Application number

NO93930199A

Other languages

English (en)

Other versions

NO930199D0 (no

NO308215B1 (no

Inventor

Eugen Uhlmann

Anuschirwan Peyman

Gerard O'malley

Matthias Helsberg

Irvin Winkler

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-22

Filing date

1993-01-21

Publication date

1993-07-23

1993-01-21 Application filed by Hoechst Ag filed Critical Hoechst Ag

1993-01-21 Publication of NO930199D0 publication Critical patent/NO930199D0/no

1993-07-23 Publication of NO930199L publication Critical patent/NO930199L/no

2000-08-14 Publication of NO308215B1 publication Critical patent/NO308215B1/no

Links

238000002360 preparation method Methods 0.000 title abstract 2
108091034117 Oligonucleotide Proteins 0.000 title 1
229910052760 oxygen Inorganic materials 0.000 abstract 4
229910052717 sulfur Inorganic materials 0.000 abstract 4
125000000217 alkyl group Chemical group 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
150000007523 nucleic acids Chemical class 0.000 abstract 2
102000039446 nucleic acids Human genes 0.000 abstract 2
125000002327 selenol group Chemical group [H][Se]* 0.000 abstract 2
108020003215 DNA Probes Proteins 0.000 abstract 1
239000003298 DNA probe Substances 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
238000009396 hybridization Methods 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000003834 intracellular effect Effects 0.000 abstract 1
238000002372 labelling Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
239000000523 sample Substances 0.000 abstract 1
229910052711 selenium Inorganic materials 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

NO930199A 1992-01-22 1993-01-21 Oligonukleotidanaloger, deres anvendelse og farmasøytiske sammensetning inneholdende disse NO308215B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4201662		1992-01-22

Publications (3)

Publication Number	Publication Date
NO930199D0 NO930199D0 (no)	1993-01-21
NO930199L true NO930199L (no)	1993-07-23
NO308215B1 NO308215B1 (no)	2000-08-14

Family

ID=6450030

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO930199A NO308215B1 (no)	1992-01-22	1993-01-21	Oligonukleotidanaloger, deres anvendelse og farmasøytiske sammensetning inneholdende disse

Country Status (17)

Country	Link
EP (1)	EP0552766B1 (no)
JP (1)	JP3717081B2 (no)
KR (1)	KR930016437A (no)
AT (1)	ATE217880T1 (no)
AU (1)	AU661365B2 (no)
CA (1)	CA2087818C (no)
DE (1)	DE59310285D1 (no)
DK (1)	DK0552766T3 (no)
ES (1)	ES2177532T3 (no)
FI (1)	FI115214B (no)
HU (1)	HU227794B1 (no)
IL (1)	IL104461A (no)
NO (1)	NO308215B1 (no)
NZ (1)	NZ245720A (no)
PL (1)	PL172257B1 (no)
PT (1)	PT552766E (no)
ZA (1)	ZA93422B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5378825A (en) *	1990-07-27	1995-01-03	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs
US5646261A (en) *	1992-01-22	1997-07-08	Hoechst Aktiengesellschaft	3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
DK0593901T3 (da) *	1992-09-24	1997-10-27	Hoechst Ag	Oligoribonucleotid- og ribozym-analoge med terminale 3-3- og 5-5-bindinger.
EP0602524A1 (de) *	1992-12-15	1994-06-22	Hoechst Aktiengesellschaft	Chemilumineszenzmarkierte Gensonden und ihre Verwendung in Gensondentesten
ATE150464T1 (de) *	1993-01-08	1997-04-15	Hybridon Inc	Synthese von dimer-blöcken und ihre verwendung bei der zusammensetzung von oligonukleotiden
US6087491A (en)	1993-01-08	2000-07-11	Hybridon, Inc.	Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
DK0677056T3 (da) *	1993-01-25	1996-08-05	Hybridon Inc	Oligonukleotid-alkylphosphonater og -alkylphosphonothioater
CA2114355A1 (en) *	1993-01-29	1994-07-30	Hidehiko Furukawa	Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
US5532130A (en) *	1993-07-20	1996-07-02	Dyad Pharmaceutical Corporation	Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
DE4331670A1 (de) *	1993-09-17	1995-03-23	Hoechst Ag	Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
DE4338704A1 (de)	1993-11-12	1995-05-18	Hoechst Ag	Stabilisierte Oligonucleotide und deren Verwendung
DE4408528A1 (de) *	1994-03-14	1995-09-28	Hoechst Ag	Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
US6919441B2 (en)	1994-03-14	2005-07-19	Aventis Pharma Deutschland Gmbh	Polyamide-oligonucleotide derivatives, their preparation and use
HUT76094A (en) *	1994-03-18	1997-06-30	Lynx Therapeutics	Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5599922A (en) *	1994-03-18	1997-02-04	Lynx Therapeutics, Inc.	Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) *	1994-03-18	1998-03-10	Lynx Therapeutics, Inc.	Oligodeoxyribonucleotide N3' P5' phosphoramidates
DE4415370A1 (de) *	1994-05-02	1995-11-09	Hoechst Ag	Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US5986076A (en) *	1994-05-11	1999-11-16	Trustees Of Boston University	Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5696248A (en) *	1994-06-15	1997-12-09	Hoechst Aktiengesellschaft	3'-modified oligonucleotide derivatives
DE4438918A1 (de) *	1994-11-04	1996-05-09	Hoechst Ag	Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US6150510A (en)	1995-11-06	2000-11-21	Aventis Pharma Deutschland Gmbh	Modified oligonucleotides, their preparation and their use
DE19502912A1 (de) *	1995-01-31	1996-08-01	Hoechst Ag	G-Cap Stabilisierte Oligonucleotide
PT739898E (pt) *	1995-03-13	2002-03-28	Aventis Pharma Gmbh	Mono-esteres de acidos fosfonucleicos processo para a sua preparacao e sua utilizacao
US6326487B1 (en)	1995-06-05	2001-12-04	Aventis Pharma Deutschland Gmbh	3 modified oligonucleotide derivatives
US5684143A (en) *	1996-02-21	1997-11-04	Lynx Therapeutics, Inc.	Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) *	1996-02-21	1999-01-12	Lynx Therapeutics, Inc.	Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
GB9606158D0 (en) *	1996-03-23	1996-05-29	Ciba Geigy Ag	Chemical compounds
ES2221942T3 (es) *	1996-05-24	2005-01-16	Aventis Pharma Deutschland Gmbh	Reactivo y metodo para inhibir la expresion de n-ras.
DE19627898A1 (de) *	1996-07-11	1998-01-15	Hoechst Ag	Festphasensynthese von Oligonucleotiden
US6723706B2 (en)	1997-05-05	2004-04-20	Aventis Pharma Deutschland Gmbh	Modified antisense nucleotides complementary to a section of the human Ha-ras gene
AU9460898A (en) *	1997-10-14	1999-05-03	Sankyo Company Limited	Modified oligodeoxyribonucleotides having tggg sequence
EP1004661A1 (de)	1998-11-11	2000-05-31	DALLI-WERKE WÄSCHE- und KÖRPERPFLEGE GmbH & Co. KG	Verdichtetes Granulat, Herstellungsverfahren und Verwendung als Sprengmittel für gepresste Formkörper (2)
DE19935303A1 (de)	1999-07-28	2001-02-08	Aventis Pharma Gmbh	Oligonukleotide zur Inhibierung der Expression von humanem eg5
DE19935302A1 (de)	1999-07-28	2001-02-08	Aventis Pharma Gmbh	Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen
DE10133915A1 (de)	2001-07-12	2003-02-06	Aventis Pharma Gmbh	Neue Oligoribonucleotid-Derivate zur gezielten Hemmung der Genexpression
CN1845993B (zh)	2003-08-28	2010-06-23	诺瓦提斯公司	具有平端和3＇修饰的干扰rna双链体
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds
EP3643782A1 (en)	2008-02-11	2020-04-29	Phio Pharmaceuticals Corp.	Modified rnai polynucleotides and uses thereof
US8815818B2 (en)	2008-07-18	2014-08-26	Rxi Pharmaceuticals Corporation	Phagocytic cell delivery of RNAI
EP2342340A1 (en)	2008-09-22	2011-07-13	Rxi Pharmaceuticals Corporation	Rna interference in skin indications
US9074211B2 (en)	2008-11-19	2015-07-07	Rxi Pharmaceuticals Corporation	Inhibition of MAP4K4 through RNAI
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2011119852A1 (en)	2010-03-24	2011-09-29	Rxi Pharmaceuticals Corporation	Reduced size self-delivering rnai compounds
CA2794189C (en)	2010-03-24	2022-01-11	Rxi Pharmaceuticals Corporation	Rna interference in dermal and fibrotic indications
US9095504B2 (en)	2010-03-24	2015-08-04	Rxi Pharmaceuticals Corporation	RNA interference in ocular indications
JP6772062B2 (ja)	2013-12-02	2020-10-21	フィオファーマシューティカルズコーポレーションＰｈｉｏＰｈａｒｍａｃｅｕｔｉｃａｌｓＣｏｒｐ．	癌の免疫療法
WO2015125845A1 (ja) *	2014-02-20	2015-08-27	塩野義製薬株式会社	含窒素非芳香族複素環を含む核酸のリン酸部位修飾
CA2947270A1 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic acids targeting mdm2 or mycn
EP3188799B1 (en)	2014-09-05	2022-07-06	Phio Pharmaceuticals Corp.	Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
US11001845B2 (en)	2015-07-06	2021-05-11	Phio Pharmaceuticals Corp.	Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11021707B2 (en)	2015-10-19	2021-06-01	Phio Pharmaceuticals Corp.	Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
JP7167059B2 (ja)	2017-04-19	2022-11-08	フィオファーマシューティカルズコーポレーション	核酸化合物の局所送達
CA3098623A1 (en)	2018-05-07	2019-11-14	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3239888A1 (de) *	1982-10-28	1984-05-03	Hubert Prof. Dr. 2000 Hamburg Köster	Verfahren zur herstellung von oligonucleosidphosphonaten
US4739044A (en) *	1985-06-13	1988-04-19	Amgen	Method for derivitization of polynucleotides
US4950745A (en) *	1986-10-30	1990-08-21	Daicel Chemical Industries, Ltd.	Process for synthesis of oligonucleotides and compound for forming polymeric protecting group
US4816571A (en) *	1987-06-04	1989-03-28	Applied Biosystems, Inc.	Chemical capping by phosphitylation during oligonucleotide synthesis
WO1991006556A1 (en) *	1989-10-24	1991-05-16	Gilead Sciences, Inc.	2' modified oligonucleotides
US5210015A (en) *	1990-08-06	1993-05-11	Hoffman-La Roche Inc.	Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
GB9021625D0 (en) *	1990-10-04	1990-11-21	Ici Plc	Synthesis of oligonucleotides

1993
- 1993-01-20 NZ NZ245720A patent/NZ245720A/en not_active IP Right Cessation
- 1993-01-20 KR KR1019930000675A patent/KR930016437A/ko not_active Ceased
- 1993-01-20 FI FI930220A patent/FI115214B/fi not_active IP Right Cessation
- 1993-01-20 IL IL10446193A patent/IL104461A/en not_active IP Right Cessation
- 1993-01-21 JP JP00839193A patent/JP3717081B2/ja not_active Expired - Lifetime
- 1993-01-21 ZA ZA93422A patent/ZA93422B/xx unknown
- 1993-01-21 ES ES93100892T patent/ES2177532T3/es not_active Expired - Lifetime
- 1993-01-21 PT PT93100892T patent/PT552766E/pt unknown
- 1993-01-21 DE DE59310285T patent/DE59310285D1/de not_active Expired - Lifetime
- 1993-01-21 AU AU31910/93A patent/AU661365B2/en not_active Expired
- 1993-01-21 EP EP93100892A patent/EP0552766B1/de not_active Expired - Lifetime
- 1993-01-21 AT AT93100892T patent/ATE217880T1/de active
- 1993-01-21 DK DK93100892T patent/DK0552766T3/da active
- 1993-01-21 CA CA002087818A patent/CA2087818C/en not_active Expired - Lifetime
- 1993-01-21 NO NO930199A patent/NO308215B1/no not_active IP Right Cessation
- 1993-01-21 HU HU9300162A patent/HU227794B1/hu unknown
- 1993-01-22 PL PL93297515A patent/PL172257B1/pl unknown

Also Published As

Publication number	Publication date
DE59310285D1 (de)	2002-06-27
PL172257B1 (pl)	1997-08-29
CA2087818C (en)	2007-07-10
DK0552766T3 (da)	2002-08-19
AU661365B2 (en)	1995-07-20
IL104461A (en)	2001-05-20
PL297515A1 (en)	1993-09-06
ES2177532T3 (es)	2002-12-16
EP0552766A2 (de)	1993-07-28
FI930220A0 (fi)	1993-01-20
ATE217880T1 (de)	2002-06-15
NZ245720A (en)	1995-12-21
EP0552766B1 (de)	2002-05-22
PT552766E (pt)	2002-10-31
KR930016437A (ko)	1993-08-26
JP3717081B2 (ja)	2005-11-16
HU9300162D0 (en)	1993-04-28
NO930199D0 (no)	1993-01-21
ZA93422B (en)	1993-09-16
AU3191093A (en)	1993-07-29
HUT63173A (en)	1993-07-28
HU227794B1 (en)	2012-03-28
FI115214B (fi)	2005-03-31
IL104461A0 (en)	1993-05-13
JPH05310779A (ja)	1993-11-22
NO308215B1 (no)	2000-08-14
EP0552766A3 (en)	1994-09-07
CA2087818A1 (en)	1993-07-23
FI930220L (fi)	1993-07-23

Legal Events

Date	Code	Title	Description
2013-02-18	MK1K	Patent expired

Publication	Publication Date	Title
NO930199D0 (no)	1993-01-21	Oligonukleotidanaloger, deres fremstilling og anvendelse
US5317098A (en)	1994-05-31	Non-radioisotope tagging of fragments
Sinha et al.	1983	β-Cyanoethyl N, N-dialkylamino/N-morpholinomonochloro phosphoamidites, new phosphitylating agents facilitating ease of deprotection and work-up of synthesized oligonucleotides
AU742241B2 (en)	2001-12-20	PNA and DNA conjugates and methods for preparation thereof
ATE242260T1 (de)	2003-06-15	Sulfonatfreie cyaninfarbstoffe zur markierung von nukleosiden und nukleotiden
ATE199725T1 (de)	2001-03-15	Synthetische katalytische oligonukleotide
ES2140551T3 (es)	2000-03-01	Nucleotidos marcados con colorantes para infrarrojos y su utilizacion en la deteccion de acidos nucleicos.
ATE174600T1 (de)	1999-01-15	2'-amido-und 2'-peptido-modifizierte oligonukleotide
KR950032265A (ko)	1995-12-20	폴리아미드-올리고뉴클레오타이드 유도체, 이의 제조방법 및 용도
DK1296997T3 (da)	2007-01-02	Baseanaloger
DE60002989D1 (de)	2003-07-03	Verfahren zur herstellung von morpholinonukleotiden und verwendung derselben zur analyse und markierung von nukleinsäuresequenzen
ATE55109T1 (de)	1990-08-15	Chemisches verfahren zur herstellung von abkoemmlingen von oxamid.
DE69501705D1 (de)	1998-04-09	Verfahren zur Herstellung von optisch aktiven Piperazinderivaten und Zwischenprodukten für ihre Herstellung
EP0462224B1 (en)	1994-08-31	Sequencing nucleic acids using chemiluminescent detection
RU92001266A (ru)	1996-04-10	Способ получения нерадиоактивномеченого зонда для определения нуклеотидных последовательностей